Skip to content

Effect of betamethasone before total knee replacement on postoperative nausea and vomiting: a prospective randomized controlled study

Effect of betamethasone before total knee replacement on postoperative nausea and vomiting: a prospective randomized controlled study

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300072532
Enrollment
Unknown
Registered
2023-06-16
Start date
2023-06-17
Completion date
Unknown
Last updated
2024-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Knee arthritis

Interventions

Test group:Application of Betamethasone
Control group:Application of normal saline

Sponsors

Department of Knee Joints, Xi'an HongHui Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
50 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Adult knee osteoarthritis patients receiving the first unilateral TKA in Xi 'an Honghui Hospital; 2. Adult patients with American Society of Anesthesiologists (ASA) functional status I-III and aged 50-80 years old gave informed consent to participate in this study.

Exclusion criteria

Exclusion criteria: 1. Cardiovascular impairment (New York Heart Association rating > 2); 2. Renal function (glomerular filtration rate B); Poor diabetes control (DM; HbA1c > 7.5%); 4. Allergy to any investigational drug; 5. Have taken any strong opioids in the past week or received systemic corticosteroid therapy within 3 months before surgery; 6. Alcohol dependence or substance abuse, such as opioid dependence (morphine, fentanyl, or oxycodone); 7. Cognitive impairment; 8. Effects of psychological and neurological impairment on pain perception; 9. Patients who stopped intravenous (IV) controlled analgesia; 10. Body mass Index (BMI) > 35 kg/m2; 11. Previous history of PONV/ motion sickness; 12. All subjects who have language impairments, are unable or unwilling to provide informed consent, or are unable to comply with the requirements of the study, are deemed by the investigator to be unsuitable for participation in the study.

Design outcomes

Primary

MeasureTime frame
Nausea level;Vomiting frequency;

Secondary

MeasureTime frame
Pain level;knee motion;C-reactive protein;erythrocyte sedimentation rate;Interleukin-6;

Countries

China

Contacts

Public ContactXiaobo Sun

Xi'an Honghui Hospital

pwj202361@163.com+86 157 3521 3367

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026